MCT1 is therefore proposed as a most likely therapeutic target for neuroblastomas and gliomas, and α-CCA has been able to suppress tumor growth via inhibition of MCT1 [5,32,33]. This evidence concerns the gene SLC16A1 and central nervous system cancer.